CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) announced its quarterly earnings data on Wednesday, September 30th. The company reported ($1.89) EPS for the quarter, beating the consensus estimate of ($2.45) by $0.56, Zacks reports. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.48 million. CollPlant Biotechnologies had a negative return on equity of 298.21% and a negative net margin of 678.37%.
CollPlant Biotechnologies Price Performance
Shares of NASDAQ:CLGN traded down $0.06 during trading on Monday, reaching $4.08. 40,494 shares of the company were exchanged, compared to its average volume of 117,357. The firm has a market capitalization of $7.71 million, a PE ratio of -0.30 and a beta of 1.65. The business’s fifty day simple moving average is $3.69 and its 200-day simple moving average is $5.23. CollPlant Biotechnologies has a 12-month low of $2.64 and a 12-month high of $22.90.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Friday, September 4th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CollPlant Biotechnologies currently has a consensus rating of “Reduce” and a consensus price target of $120.00.
Check Out Our Latest Stock Analysis on CollPlant Biotechnologies
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an Israel-based biotechnology company developing regenerative medicine products and technologies based on plant-derived recombinant human collagen, or rhCollagen. The company produces collagen using genetically engineered tobacco plants, an approach designed to provide a consistent, scalable and animal-free source of collagen for medical applications.
CollPlant’s technology platform is intended for use in tissue regeneration, wound care, medical aesthetics and 3D bioprinting.
See Also
- Five stocks we like better than CollPlant Biotechnologies
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
